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EVALUATING COSTS WITH UNMEASURED CONFOUNDING:
A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT
By Elizabeth A. Handorf1,∗, Justin E. Bekelman2,†,
Daniel F. Heitjan3,† and Nandita Mitra3,†
Fox Chase Cancer Center∗ and University of Pennsylvania†
Estimates of the effects of treatment on cost from observational
studies are subject to bias if there are unmeasured confounders. It
is therefore advisable in practice to assess the potential magnitude
of such biases. We derive a general adjustment formula for loglin-
ear models of mean cost and explore special cases under plausible
assumptions about the distribution of the unmeasured confounder.
We assess the performance of the adjustment by simulation, in par-
ticular, examining robustness to a key assumption of conditional in-
dependence between the unmeasured and measured covariates given
the treatment indicator. We apply our method to SEER-Medicare
cost data for a stage II/III muscle-invasive bladder cancer cohort.
We evaluate the costs for radical cystectomy vs. combined radia-
tion/chemotherapy, and find that the significance of the treatment
effect is sensitive to plausible unmeasured Bernoulli, Poisson and
Gamma confounders.
1. Introduction. Payers and health care providers, such as Medicare, pri-
vate insurers and hospitals, routinely collect data on medical expenditures
[Hornberger and Wrone (1997)]. Some of these data sources are readily avail-
able and have high external validity [Black (1996)] and therefore are widely
used to compare treatment costs. Like all observational data, however, they
are subject to confounding. That is, if all relevant confounders are mea-
sured and present in the data set, we can find a consistent estimate of the
treatment effect by using a correctly specified statistical model for cost. If
some confounders are unmeasured or unavailable, the model-based estimate
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is potentially biased. Here we develop a method to assess the sensitivity to
potential unmeasured confounders when evaluating the effect of a medical
intervention on mean cost.
Cost data are nonnegative and often highly skewed, features that can be
readily described statistically in the generalized linear model framework. For
example, a Gamma regression with a log link is often a suitable model for
cost data [Dodd et al. (2006)]. The situation is more complex when some
costs are censored. Costs accrue over time, and they may accrue at different
rates among individuals. Therefore, cost at the time of censoring is gener-
ally correlated with cost at the time of ultimate failure, making censoring
informative [Lin et al. (1997), Etzioni et al. (1999)]. One popular method
which accounts for this is Inverse Probability Weighting (IPW), where ob-
served costs are weighted by the inverse probability of censoring [Lin (2000,
2003), Bang and Tsiatis (2000, 2002), Willan et al. (2002), Tian and Huang
(2007)]. In the context of observational cost data, the method of Lin (2003)
is particularly useful. He applies IPW to generalized linear models, allow-
ing adjustment for confounders in a Gamma regression. Other approaches
which handle informative censoring are based on Bayesian methods or use
multi-part models [Heitjan, Kim and Li (2004), Basu and Manning (2010),
Liu, Huang and O’Quigley (2008), Liu (2009)].
The methods cited above do not address the potential bias due to unmea-
sured confounding. A natural approach to evaluate this bias is a sensitivity
analysis, in which one posits models for the distribution of an unmeasured
confounder and its effects on cost, then evaluates their effects on estimates
of the treatment effect. Researchers have developed various methods im-
plementing this idea [Rosenbaum and Rubin (1983a), Schlesselman (1978),
Yanagawa (1984), Axelson and Steenland (1988), Gail, Wacholder and Lu-
bin (1988), Flanders and Khoury (1990), McCandless, Gustafson and Levy
(2007), Hosman, Hansen and Holland (2010)]. Further developments include
the method of Lin, Psaty and Kronmal (1998), in which the authors present
a formula to determine the magnitude of the bias due to an unmeasured
Bernoulli or Normal covariate. Mitra and Heitjan (2007) extended this idea
to assess the sensitivity of survival outcomes using a Weibull model.
As we have indicated, the method of Lin, Psaty and Kronmal (1998) as-
sesses the sensitivity of the treatment effect to unknown binomial or normal
confounders. Wang and Krieger (2006) have shown that in a matched pairs
study, conclusions are most sensitive to a Bernoulli confounder and, thus,
such an analysis is sufficient to describe maximal sensitivity. It is unclear
whether an analogous result holds in cohort studies, however, or indeed
whether the exploration of maximal sensitivity is most desirable in every
context. Therefore, in this paper we generalize the Lin method to derive
corrections for a broader range of distributions of unmeasured confounders.
For example, applying our formula for a Gamma confounder, one can adjust
for an unmeasured skewed continuous variable such as personal income. Or
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using our formula for a Poisson confounder, one can adjust for an unmea-
sured count variable such as pack-years smoked.
A major drawback of the Lin method and related sensitivity analyses
for the effects of an unmeasured confounder is the assumption of indepen-
dence between measured and unmeasured confounders given treatment sta-
tus. Herna´n and Robins (1999) demonstrated that such an assumption is
implausible, as conditioning on treatment induces a correlation even be-
tween unrelated covariates. VanderWeele (2008) showed how one of Lin’s
formulas can apply in certain circumstances with relaxed assumptions, and
VanderWeele and Arah (2011) developed bias adjustment formulas that are
valid more generally without requiring conditional independence. The im-
plementation of these approaches can be complex, however, and a simpler
alternative such as the Lin method would be invaluable in applications. In
this paper, therefore, we both extend the basic Lin method to a range of log-
linear models and use simulations to explore the limits of its validity under
departures from conditional independence.
We demonstrate our method with a comparison of mean medical costs for
two treatments for stage II/III muscle-invasive bladder cancer. As this is the
ninth costliest cancer [National Cancer Institute (2011)], it is of substantial
interest to determine cost-effective treatments for it. Here, we compare the
lifetime costs for radical cystectomy, an aggressive surgical procedure that
is the current standard of care, to combined radiotherapy and chemother-
apy, an alternative organ-sparing curative treatment. The data are censored
because many registry participants were still living when the database was
closed. We base our cost comparisons on observational data from the linked
SEER-Medicare registry, assessing the sensitivity of the treatment effect to
potential Bernoulli, Poisson and Gamma unmeasured confounders.
The paper is organized as follows: in Section 2 we develop a general for-
mula to quantify the magnitude of the bias of treatment effect due to an
unknown confounder, and derive the correction for Poisson and Gamma con-
founders. We further show how these formulas and those of Lin et al. [Lin,
Psaty and Kronmal (1998)] can be used to assess sensitivity with cost data,
including censored costs. We specifically address criticisms that have been
raised of the assumption of conditional independence of observed and unob-
served covariates given treatment. In Section 3 we assess the performance
of our method using Monte Carlo simulations, evaluating robustness to de-
partures from conditional independence. In Section 4 we apply our method
to the SEER bladder cancer data.
2. Bias with an unmeasured confounder. We first consider uncensored
costs. Assuming a generalized linear model (GLM) with a log link, we define
the true model as
E(Y |X,Z,U) = exp(α+ β0X + φ0U +ψ1XU + θ
′Z),
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where Y is the total cost, X is the treatment of interest (X = 0 for control
and X = 1 for treated), U is the unmeasured confounder and Z is a vector of
measured covariates. The true regression parameters are α, β0, θ, φ0 and ψ1.
We allow the unmeasured confounder U to have different effects on cost in
the treatment groups, so β0 is the effect of X when U = 0, and β0+ψ1 is the
effect of X when U is nonzero. Likewise, φ0 is the effect of U in the control
group, and φ0 +ψ1 is the effect of U in the treated group. For convenience,
we express the model as
E(Y |X,Z,U) = exp(α+ β0X + γXU + θ
′Z).(1)
This is equivalent to the model specified above, where γ0 is the effect of
U in the control group and γ1 is the effect of U in the treated group. For
simplicity, we henceforth suppress the subscript in β0.
In practice, we cannot fit model (1) because we do not know the value of
U . We define the reduced model, which we can fit, as
E(Y |X,Z) = exp(α∗ + β∗X + θ∗′Z).(2)
Fitting model (2) yields an estimate of the apparent treatment effect β∗.
By conditional expectation,
E(Y |X,Z) =
∫ ∞
−∞
E(Y |X,Z,U)dF (U |X,Z)
= exp(α+ βX + θ′Z)
∫ ∞
−∞
exp(γXU)dF (U |X,Z)
= exp(α+ βX + θ′Z)MU |X,Z(γX),
where MU |X,Z(γX) is the moment generating function (m.g.f.) of U |X,Z.
If we assume that U is conditionally independent of Z given X so that
MU |X,Z(γX) =MU |X(γX), the following simplification is possible:
E(Y |X,Z) = exp(α+ ln(MU |0(γ0))
(3)
+X[β + ln(MU |1(γ1))− ln(MU |0(γ0))] + θ
′Z).
Setting (2) equal to (3) gives
β = β∗ − ln(MU |X=1(γ1)) + ln(MU |X=0(γ0)).(4)
Thus, we can conduct a sensitivity analysis by positing distributions for U |X
and values for γX in the treated and control groups. Equation (4) holds for
any distribution of U that one can characterize by a moment-generating
function, a large class of distributions. In the following sections we show the
solutions for β when U is distributed as Poisson or Gamma. We also present
the formulas developed by Lin, Psaty and Kronmal (1998) for Bernoulli and
Normal unmeasured confounders, and show how they are applicable in the
cost setting.
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2.1. Poisson unmeasured confounder. For U ∼ Poisson(λX,Z), we have
MU |X,Z(γX) = exp(λX,Z(e
γX − 1)),
and under conditional independence (λX,Z = λX), (4) becomes
β = β∗ − (λ1e
γ1 − λ0e
γ0 + λ0 − λ1),
where λ0 is the mean of U in the control group and λ1 is the mean in the
treated group, β is the true treatment effect, β∗ is the observed treatment
effect, and γ0 and γ1 are the effects of U in the control and treated groups,
respectively.
2.2. Gamma unmeasured confounder. An unobserved covariate
U ∼Gamma(θX,Z , κX,Z)
has m.g.f.
MU |X,Z(γX) = (1− θX,ZγX)
−κX,Z .
Under conditional independence (θX,Z = θX , κX,Z = κX ), (4) implies
β = β∗ − ln
(1− θ0γ0)
κ0
(1− θ1γ1)κ1
,
where the mean and variance of U are κ0θ0 and κ0θ
2
0 for the control group
and κ1θ1 and κ1θ
2
1 for the treated group.
2.3. Bernoulli and Normal unmeasured confounders. Lin, Psaty and Kro-
nmal (1998) derived the relationship between the true and apparent treat-
ment effects for a binary outcome with a log link when unmeasured con-
founders are Bernoulli or Normal. Because the derivation also applies to a
continuous outcome with a log link, their results are special cases of (4).
Specifically, if U ∼ Bernoulli(piX,Z), and U is conditionally independent of
Z (piX,Z = piX), then
β = β∗ − ln
eγ1pi1 + (1− pi1)
eγ0pi0 + (1− pi0)
,
where pi0 is the prevalence of U in the control group, pi1 is the prevalence of
U in the treated group, and the other parameters are as above. Similarly, if
U ∼ Normal(µX,Z ,1) and again is conditionally independent of Z (µX,Z =
µX), then
β = β∗ + (µ0γ0 − µ1γ1 + (γ
2
0 − γ
2
1)/2),
where µj is the mean of U in treatment group j, j = 0,1, and β, β
∗, γ0 and
γ1 are as above.
2.4. Assumption of conditional independence. The conditional indepen-
dence assumption (that U is conditionally independent of Z given X) cannot
be tested in practice since U is not observed. However, it has been well-
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established that the assumption cannot actually hold in practice. Condi-
tional independence would hold if the marginal correlation perfectly cancels
the conditional correlation or if the covariates Z are not truly confounders,
but either condition is highly improbable. Herna´n and Robins (1999) ob-
served that conditional independence cannot hold if Z and U are marginally
independent and are both confounders. VanderWeele (2008) showed that
closed-form solutions are available for normal unmeasured confounders and
for a binary confounder with a normal outcome under a relaxed additivity
assumption. VanderWeele and Arah (2011) developed general formulas for
calculating an adjusted estimate of the treatment effect without assumptions
about the relationship between the measured and unmeasured covariates. In
the most general case one must specify E(Y ) at each level of X , U and Z.
When U or Z is continuous, this would be very difficult to implement in
practice. For the case where the relationship between Y and U is constant
across levels of Z, as would occur in a linear model, VanderWeele and Arah
(2011) developed simplified formulas that require fewer sensitivity parame-
ters. In our loglinear regression setting, however, an additional bootstrapping
approach would be required to use these formulas.
Although we do not expect our corrections to hold exactly in practice due
to weak tenability of the conditional independence assumption, if conditional
dependence is modest, they may still be useful. In Section 3.2 we present
simulations to investigate the effect of dependence within treatment strata.
2.5. Analysis with censored costs. We derived our adjustment formu-
las assuming uncensored data; nevertheless, because they are statements
about parameters, they are valid also in the censored case provided that
one estimates the parameters consistently. Lin (2003) developed a general-
ized regression method, appropriate for censored costs, that combines the
generalized estimating equation approach with inverse probability of cen-
soring weighting. This approach produces consistent estimates but forfeits
efficiency because it uses only the uncensored data. Bang and Tsiatis (2002)
developed a more efficient estimator for linear regression that uses all of the
data, but an extension to the GLM has yet to be developed. We therefore
recommend using the Lin (2003) approach, but note that our formulas are
applicable with any method that gives consistent estimates for a loglinear
mean model.
2.6. Sensitivity analysis for cost regression. The sensitivity analysis pro-
ceeds in four steps: first, estimate β∗ in (2) by any consistent method. Sec-
ond, specify the type of the unmeasured confounder: for example, Poisson
for a count confounder; Gamma for skewed, positive continuous; Normal for
symmetric continuous; and Bernoulli for binary. Third, hypothesize possible
parameter values η for the distributions of the unmeasured confounder in
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the treated and control groups, and also the possible effect γ of the unmea-
sured confounder on cost. Finally, apply the correction via (4) to obtain βˆ,
the adjusted treatment effect.
The analysis assumes that the sensitivity parameters η are known. Be-
cause the adjustment is in every case additive, it follows that
Var(βˆ|X,Z,η) = Var(βˆ∗|X,Z).
We use this relationship to calculate confidence intervals and determine the
significance of the adjusted treatment effect, as was done by Lin, Psaty
and Kronmal (1998), Mitra and Heitjan (2007) and VanderWeele and Arah
(2011). Note that this does not imply that Var(βˆ|X,Z,U) = Var(βˆ∗|X,Z).
If we were able to measure U , the variance of our estimate of β would
be smaller, however, our correction does not reduce the uncertainty of our
estimate, only the bias. Therefore, the appropriate variance estimate for the
corrected βˆ is Var(βˆ∗|X,Z). We confirm this via simulation in Section 3.1
where we show that coverage probabilities are close to the nominal level,
indicating that Var(βˆ∗|X,Z) is a reasonable estimate for the variance of the
corrected treatment effect.
The investigator should repeat this procedure for a range of combinations
of parameter values and effect sizes, assessing the plausibility of any combi-
nation of inputs that materially changes the conclusions. If the significance
of the treatment effect changes due to unmeasured confounders with a small
effect on cost and similar distributions in the treated and control groups,
one can conclude that inferences are vulnerable to the effects of unmeasured
confounding. We demonstrate the procedure in Section 4.
3. Simulations. The general plan of the simulations was to generate costs
knowing the values of both measured and unmeasured covariates, then fit
the reduced regression omitting the unmeasured covariate and compute the
adjusted treatment effect. We evaluated performance by the bias of the ad-
justed estimate and the coverage probability of the resulting 95% confidence
interval.
3.1. Method performance. Initial simulations evaluated the performance
of the method under independence of the unmeasured confounder U and
measured confounder Z given treatment status X . We constructed 1000
replications in each simulation, with 100, 200 and 500 subjects per treatment
stratum. We drew U independently from its distribution fU (U |X,ηX) using
the parameter values ηX shown in Table 1. For example, a Poisson unmea-
sured confounder was Poisson(λ= 1) in the control group and Poisson(λ=
1.58) in the treated group. We next drew a scalar measured confounder Z,
which can represent either a single confounder or a linear combination of a
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Table 1
Monte Carlo simulations of the adjusted treatment effect, n= 100 per treatment stratum
Mean of βˆ† (coverage probability)
Distribution γ Uncensored 25% censoring 50% censoring 75% censoring
Bernoulli⋄ 0.25 0.999 (0.963) 1.001 (0.925) 1.001 (0.933) 0.997 (0.817)
0.5 1.001 (0.958) 0.998 (0.936) 1.003 (0.885) 1.004 (0.790)
0.75 1.000 (0.954) 1.004 (0.924) 0.999 (0.918) 1.005 (0.780)
1 1.003 (0.946) 1.007 (0.935) 1.008 (0.909) 1.016 (0.744)
Normal∗ 0.25 1.001 (0.931) 0.996 (0.950) 1.000 (0.911) 1.000 (0.856)
0.5 1.002 (0.949) 1.000 (0.950) 1.006 (0.910) 0.995 (0.841)
0.75 1.010 (0.946) 0.994 (0.928) 1.003 (0.924) 0.983 (0.841)
1 1.006 (0.941) 0.995 (0.923) 0.982 (0.892) 1.028 (0.815)
Poisson‡ 0.25 1.002 (0.959) 1.003 (0.943) 1.001 (0.935) 0.998 (0.841)
0.5 0.994 (0.939) 0.995 (0.936) 0.986 (0.899) 0.994 (0.804)
0.75 0.981 (0.924) 0.979 (0.892) 0.965 (0.873) 0.895 (0.768)
1 0.925 (0.894) 0.922 (0.850) 0.877 (0.828) 0.811 (0.758)
Gamma△ 0.25 1.001 (0.957) 0.999 (0.948) 1.002 (0.924) 0.996 (0.855)
0.5 0.999 (0.947) 0.997 (0.919) 0.996 (0.910) 0.997 (0.851)
0.75 0.998 (0.951) 0.989 (0.913) 0.970 (0.893) 0.957 (0.840)
1 0.931 (0.881) 0.908 (0.853) 0.915 (0.847) 0.882 (0.780)
†For all models, the true value of β is 1.
⋄Unmeasured Bernoulli covariate with pi0 = 0.3, pi1 = 0.866.
∗Unmeasured Normal covariate with µ0 = 0, µ1 = 1, σ0 = σ1 = 1.
‡Unmeasured Poisson covariate with λ0 = 1, λ1 = 1.58.
△Unmeasured Gamma covariate with κ0 = κ1 = 0.75, θ0 = 0.5, θ1 = 0.868.
vector Z. Each Z was an independent draw from a Normal distribution with
variance 1 and mean 0 in the control group and mean 1 in the treated group.
We computed the mean cost according to (1), where α= 5, β = 1, θ = 1, and
γ0 = γ1 = γ. We drew cost outcomes from fY (Y |X,Z,U), where fY was the
Gamma with variance equal to the mean. We drew censoring indicators using
a Bernoulli with varying probabilities as indicated in Table 1. We drew fail-
ure times from the Exponential with mean 5 and censoring times uniformly
over [0,10], independently of both treatment group and costs. It was only
necessary to identify the subjects with censored costs, not generate their ac-
tual censored cost values, because the IPW method uses only noncensored
observations [Lin (2003)]. In each replication, we calculated βˆ∗ from the ap-
parent model and βˆ from the adjustment formula. For uncensored data, we
used the Gamma GLM, and for censored data the IPW estimator.
Results of the simulation with 100 subjects per treatment stratum ap-
pear in Table 1. We observe that the correction worked well for Bernoulli
and Normal confounders with modest censoring. As the proportion censored
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increased, coverage probability declined from the nominal level, although the
bias remained small. For example, the treatment effect with a Bernoulli un-
measured confounder of effect size γ = 0.5 had a coverage probability of
0.96 with 0% censoring and 0.79 with 75% censoring, yet the mean of βˆ
remained close to its true value of 1 regardless of censoring. The method
worked well for Poisson and Gamma confounders with moderate effect sizes
(γ ≤ 0.5), but as the effect of U drew close to the effect of X , the corrected
βˆ incurred a bias and coverage probabilities fell below nominal levels. For
example, with Gamma U and uncensored costs, if the effect of U was small
(γ = 0.25), the bias of βˆ was 0% with a coverage probability of 0.96, but if
the effect was large (γ = 1), the bias was −7% with a coverage probability of
0.88. Increased proportions of censoring further degraded the performance
of the estimator. In the uncensored case, increasing the sample size to 2000
per treatment stratum resulted in negligible bias even for large effects (not
shown). We conclude that with substantial confounding the adjusted esti-
mates may incur bias in samples of moderate size.
With Gamma and Poisson confounders, 1%–4% of the reduced regression
models failed to converge. This occurred only when U had a large effect
on cost (γ ≥ 0.75). Analysis of the simulation data revealed that all true
models converged, and reduced models failed only when there were single
large outliers. Therefore, divergence of the reduced model may itself serve
as an indicator of misspecification due to an unmeasured confounder.
3.2. Sensitivity to departures from conditional independence. A second
set of simulations assessed robustness to violations of conditional indepen-
dence. Following Herna´n and Robins (1999) and VanderWeele (2008), we
generated the treatment X conditional on the confounders. We first drew
Z ∼ Normal(1,1), then U ∼ fU (U |Z = z) defined as follows: Bernoulli(pi =
expit(0.5 + 0.2z)); Normal(µ = 1 + 0.1z,σ = 1); Poisson(λ = 0.9 + 0.1z); or
Gamma(κ= 0.5, θ = 0.65+0.2|z|). With these parameters the unconditional
correlation between Z and U is approximately 0.1. Next, we generated
X ∼Bernoulli(Pr(X = 1) = expit(φ1+φ2z +φ3u)), varying φ1, φ2, φ3 to ob-
tain different patterns of correlation. As before, we drew costs from a Gamma
with mean function (1).
Figure 1 plots the bias in the corrected estimate vs. the maximum ab-
solute within-stratum correlation (the larger of the correlations in the two
treatment strata) for n= 500 under 25% censoring. We see that with corre-
lations above 0.15, biases exceeded 5% even for moderate effect sizes, and
the bias increased with the strength of U . Figure 2 plots the bias of the
adjusted estimate vs. that of the unadjusted estimate, revealing that the
adjustment was substantially more accurate in all cases. Figure 3 plots the
coverage probability vs. the maximum absolute within-stratum correlation.
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Fig. 1. Bias of treatment effect.
We note that effects on coverage probability can be large for modest partial
correlations, even when the confounder effect size is also modest.
For example, consider a Bernoulli U where γ = 0.75 with φ1 =−1, φ2 = 1,
and φ3 = 2. For these parameters, the partial correlation of U and Z is
−0.086 in the X = 1 stratum and −0.046 in the X = 0 stratum. Whereas
the unadjusted estimate of β has a bias of 30.8% with 0% coverage, the
adjusted treatment effect has a bias of only 1.6% and a coverage of 98.6%.
In further simulations, we explored the relative importance of correlations
between U and individual elements of Z vs. the aggregate correlation of U
with a summary of Z. We generated a four-variate normal vector (U,Z)
where U was a scalar unmeasured confounder and Z was a trivariate mea-
sured confounder, assuming two different correlation models: in model 1,
the correlations between U and elements of Z were all set to 0.1; in model
Fig. 2. Reduction in bias from unadjusted estimate.
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Fig. 3. Coverage of treatment effect.
2, the correlations were 0.3, −0.4 and 0. We then generated the treatment
indicators and computed the propensity scores [estimated e=Pr(X = 1|Z)]
[Rosenbaum and Rubin (1983b)] to summarize the effects of Z. Although
individual partial correlations were larger in model 2 than model 1, within-
stratum correlations between U and the propensity score were moderate un-
der both models (e.g., −0.02 in the X = 1 stratum and −0.10 in the X = 0
stratum under model 2). Biases were 0% for model 1 and 2% for model 2.
Thus, the simulation, although not exhaustive, suggested that the total cor-
relation of U with the propensity score is more important than individual
correlations between U and elements of Z. We also considered the effect
of the unconditional correlation between U and Z on bias and coverage.
Briefly, larger unconditional correlations of 0.2 and 0.3 led to larger within-
stratum correlations, but the bias was largely driven by the within-stratum
correlation.
Our simulations suggest that our correction is useful for moderately strong
unmeasured confounders when the total within-stratum correlation between
the unmeasured and measured confounders is less than 0.15. While the ad-
justed treatment effect may have some residual bias under conditional depen-
dence, it can still give the investigator a sense of how strongly an unmeasured
confounder might influence the treatment effect.
4. Bladder cancer study. We have applied our method to data from a co-
hort of stage II/III bladder cancer patients diagnosed between 1995 and 2005
and appearing in the linked SEER-Medicare data set [Schrag et al. (2005),
Yabroff et al. (2008)]. We restrict analysis to the two main treatments: the
standard therapy of radical cystectomy, and a bladder-sparing regimen con-
sisting of radiotherapy and cisplatin-based chemotherapy (rad/chemo). We
12 HANDORF, BEKELMAN, HEITJAN AND MITRA
excluded patients who were diagnosed before age 65, for whom bladder can-
cer was not the first primary malignancy, who did not have continuous
Medicare part A/B coverage or who had coverage from an HMO during
the treatment period, or for whom key data such as histology were missing.
Radiotherapy and chemotherapy could be given up to 3 months apart, so in
order to avoid survivorship bias, we excluded patients who died before 90
days. The final cohort included 1860 patients, of whom 77.4% were treated
with cystectomy.
We extracted payment data for Medicare parts A and B from the Carrier
Claims file, the Outpatient file, and the Medicare Provider Analysis and
Review Record. These files contained payment information for physicians,
outpatient services from institutions such as hospitals and health clinics,
and inpatient services from hospitals and long-term care facilities [National
Cancer Institute (2010)]. All payments were adjusted to year 2000 dollars
using the Medicare Economic Index [Yabroff et al. (2008), Centers for Medi-
care and Medicaid Service (2010)]. This method allowed us to compare total
costs of care rather than costs due to treatment only. Two patients had zero
costs, suggesting some incompleteness in the payment data; we corrected for
this by adding half of the lowest nonzero cost to all observations [Mosteller
and Tukey (1977)].
We modeled costs using a GLM with a log link and a gamma variance
function. Because the observed total costs were subject to censoring, we es-
timated the model by the IPW method [Lin (2003)]. Our analysis considered
all health care costs, for which the censoring rate was a moderate 39.0%.
Using a Gamma GLM accounting for censoring, we estimated the effect
of rad/chemo on cost, adjusting for the available measured covariates tumor
grade, sex, ethnicity, marital status, age, median income of the census tract,
size of the metropolitan area, number of comorbidities, year of diagnosis
and SEER site. We found that rad/chemo lowers the cost of treatment by a
factor of 0.873 (95% CI: 0.793, 0.960).
4.1. Potential magnitude of conditional correlation. To determine the
plausible extent of violations of the assumption Z ⊥ U |X , we calculated
partial correlations between each of the measured confounders, Zj , and the
combined effect of the other covariates estimated by the propensity score
excluding Zj . Some individual pairwise correlations are substantial, for ex-
ample, the correlation between sex and marital status among the treated
is −0.405. When considering the aggregate correlation with all other con-
founders, however, we found that correlations were typically smaller, often
less than 0.1 (see Table 2). The highest combined within-stratum corre-
lations were with race, with the largest observed correlation being 0.148.
Although we can never be sure of the magnitude of correlations between
U and Z, if aggregate correlations with the unmeasured confounder are no
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Table 2
Observed correlations in bladder cancer study
Corr with propensity score Largest individual corr
Unconditional Rad/chemo Cystectomy Rad/chemo Cystectomy
Grade
1 0.004 −0.004 0.000 0.150 0.082
3 0.006 −0.085 0.024 0.153 0.124
4 −0.007 0.076 −0.013 0.183 0.136
5 −0.006 0.049 −0.051 0.153 0.061
Sex −0.021 −0.035 −0.059 −0.405 0.373
Race
White 0.140 0.111 0.148 −0.189 −0.235
Black −0.075 −0.070 −0.084 0.235 0.177
Other −0.125 −0.099 −0.125 0.167 0.381
Hispanic −0.074 −0.001 −0.071 0.264 0.202
Marital status
Married −0.003 −0.001 0.012 0.384 0.373
Unmarried 0.014 0.007 0.003 0.405 0.351
Unknown −0.032 −0.017 −0.044 0.153 0.322
Age 0.134 0.115 0.061 0.199 0.162
Urban Category
1 −0.053 −0.066 −0.043 −0.408 −0.311
2 0.013 0.009 0.005 0.328 0.297
3 0.048 0.067 0.045 0.490 0.359
Comorbidities
0 −0.043 −0.044 −0.019 0.097 −0.097
1 −0.071 −0.075 −0.051 0.128 0.066
2 or more 0.091 0.093 0.058 0.140 0.108
more extreme than the highest observed value, our procedure will yield valid
results.
Because our unadjusted estimate was statistically significant, we were pri-
marily interested in assessing potential unmeasured confounders that would
displace the effect of treatment toward the null. To this end, we posited
three potential confounders: access to health care, manifested as a Bernoulli
variable; smoking history, manifested as Poisson; and personal income, man-
ifested as Gamma.
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Table 3
Sensitivity of the estimated bladder cancer treatment cost ratio to an
unmeasured Bernoulli confounder
pi0 pi1 Effect of confounder Cost ratio 95% CI
0.7 0.5 1.1 0.89 (0.81, 0.98)
0.8 0.4 1.1 0.91 (0.82, 1.00)
0.8 0.3 1.1 0.92 (0.83, 1.01)
0.7 0.5 1.25 0.91 (0.83, 1.00)
0.8 0.4 1.25 0.95 (0.87, 1.05)
0.8 0.3 1.25 0.97 (0.89, 1.07)
0.7 0.5 1.5 0.94 (0.86, 1.04)
0.8 0.4 1.5 1.02 (0.93, 1.12)
0.8 0.3 1.5 1.06 (0.97, 1.17)
Unadjusted cost ratio = 0.87 (95% CI 0.79–0.96).
Boldface confidence intervals denote changes from the unadjusted inference.
pi0 = prevalence of unmeasured confounder in cystectomy group.
pi1 = prevalence of unmeasured confounder in rad/chemo group.
4.2. Unmeasured Bernoulli confounder. Although this cohort had Medi-
care insurance that guaranteed coverage of their care, other factors that are
unavailable in SEER-Medicare such as lack of transportation or low physi-
cian availability may have limited access [Penchansky and Thomas (1981)].
For example, if rad/chemo patients had poorer access, their overall medical
costs may also have been lower. We performed a sensitivity analysis to de-
termine how strong this unmeasured confounder would need to be to explain
the treatment effect on costs. As access to health care is a difficult concept
to quantify, we categorized it as binary, with U = 1 representing good access
and U = 0 poor access.
Our sensitivity analysis (Table 3) varied both the effect of U on expected
cost and the distributions of U in the treatment strata. We see that moder-
ate imbalances in U produced tangibly different inferences from the original
analysis, even when the effect of the unmeasured confounder was small. The
adjusted treatment effect was nonsignificant when the prevalence of good
access to care was 80% in the cystectomy group and 40% in the rad/chemo
group and the confounder had an effect of 1.1 on the cost ratio. Alterna-
tively, if the effect of access on cost was 1.25, prevalences of 70% in the
cystectomy group and 50% in the rad/chemo group produced nonsignificant
confidence intervals. We conclude that although the apparent treatment ef-
fect is significant, this could be easily explained by an unmeasured Bernoulli
confounder.
4.3. Unmeasured Poisson confounder. Smoking is a major risk factor
for bladder cancer [Baris et al. (2009)] and for co-morbid conditions such as
lung and artery disease [Freund et al. (1993)]. Treating these conditions is
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Table 4
Sensitivity of the estimated bladder cancer treatment cost ratio to an
unmeasured Poisson confounder
λ0 λ1 Effect of confounder Cost ratio 95% CI
15 13 1.005 0.88 (0.80, 0.97)
15 11 1.005 0.89 (0.81, 0.98)
17 11 1.005 0.90 (0.82, 0.99)
19 11 1.005 0.91 (0.83, 1.00)
19 9 1.005 0.92 (0.83, 1.01)
15 13 1.01 0.89 (0.81, 0.98)
15 11 1.01 0.91 (0.83, 1.00)
17 11 1.01 0.93 (0.84, 1.02)
30 28 1.005 0.88 (0.80, 0.97)
30 26 1.005 0.89 (0.81, 0.98)
32 26 1.005 0.90 (0.82, 0.99)
34 26 1.005 0.91 (0.83, 1.00)
34 24 1.005 0.92 (0.83, 1.01)
30 28 1.01 0.89 (0.81, 0.98)
30 26 1.01 0.91 (0.83, 1.00)
32 26 1.01 0.93 (0.84, 1.02)
Unadjusted cost ratio = 0.87 (95% CI 0.79–0.96).
Boldface confidence intervals denote changes from the unadjusted inference.
λ0 =mean of unmeasured confounder in cystectomy group.
λ1 =mean of unmeasured confounder in rad/chemo group.
likely to increase costs. It is common to quantify smoking history in pack-
years, defined as the number of packs smoked per day times the length of
smoking in years; because this is a discrete count variable, it is natural to
model it as Poisson [see Wang and Heitjan (2008)]. Smoking intensity is
related to medical costs; a decrease of 20 pack-years has been associated
with 10% lower costs [Leigh, Hubert and Romano (2005)]. This means that
we could expect costs to increase by a factor of approximately 1.005 per
additional pack-year smoked. We estimate the mean number of pack-years
in our bladder cancer population to be between 15 and 30 [Baris et al.
(2009)]. If exposure differs between treatment strata, the treatment effect
may be subject to unmeasured confounding.
Table 4 presents the sensitivity analysis for smoking history. A single pack-
year of smoking will not affect costs substantially, so moderate differences in
smoking history between the groups are required to change the significance
of the treatment effect. If the effect of a single pack-year on cost is 1.005, an
average of 34 pack-years in the cystectomy group and 26 pack-years in the
rad/chemo group would yield a nonsignificant confidence interval. Because
a difference this large is plausible, we deem that the treatment effect is
sensitive to smoking history manifested as a Poisson confounder.
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Table 5
Sensitivity of the estimated bladder cancer treatment cost ratio to an unmeasured
Gamma confounder
Mean0/Mean1 Var/Meanp Effect of confounder Cost ratio 95% CI
1.1 2 1.05 0.88 (0.80, 0.97)
1.25 2 1.05 0.89 (0.81, 0.98)
1.5 2 1.05 0.91 (0.83, 1.01)
1.1 3 1.05 0.89 (0.81, 0.98)
1.25 3 1.05 0.91 (0.82, 1.00)
1.5 3 1.05 0.94 (0.85, 1.03)
1.1 2 1.1 0.89 (0.81, 0.98)
1.25 2 1.1 0.92 (0.83, 1.01)
1.5 2 1.1 0.96 (0.87, 1.06)
1.1 3 1.1 0.90 (0.82, 0.99)
1.25 3 1.1 0.95 (0.86, 1.04)
1.5 3 1.1 1.02 (0.92, 1.12)
Unadjusted cost ratio = 0.87 (95% CI 0.79–0.96).
Boldface confidence intervals denote changes from the unadjusted inference.
Mean0 =mean of unmeasured confounder in cystectomy group.
Mean1 =mean of unmeasured confounder in rad/chemo group.
Meanp =mean pooled across both groups.
4.4. Unmeasured Gamma confounder. Income is positively associated
with health care spending at the population level [Di Matteo (2003), Centers
for Medicare and Medicaid Service (2003)]. Median income for the census
tract was available in SEER-Medicare data, and our analysis showed no
evidence of imbalance on aggregate, but there was still a possibility of im-
balance at the patient level. We therefore hypothesized that an effect of
income on spending would be small, and a potential imbalance of income
between the patient groups would also be small.
Income distributions are heavy-tailed. According to the U.S. census [US
Census (2008)], the ratio of the variance to the mean (θ in the Gamma dis-
tribution) is approximately 3 for households with members 65 and older. We
took income to be measured as a ratio of individual income to mean income.
Therefore, if the true effect of income was 1.25, an increase from the mean to
twice the mean would cause a 25% increase in medical spending. We further
assumed equal θ across treatment strata. Our sensitivity analysis (Table 5)
revealed that the treatment effect on cost became nonsignificant when in-
come was 25% higher in the cystectomy group than the rad/chemo group if
the effect of income on spending was only 1.05 and θ = 3. As such small dif-
ferences and effect sizes are plausible, we conclude that the treatment effect
is also sensitive to this Gamma confounder.
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5. Conclusion. We have developed a method to correct estimates of the
treatment effect on mean cost for a range of potential unmeasured con-
founders. The method is simple to apply and readily accommodates po-
tential binary, count and continuous confounders. Although it assumes in-
dependence of the measured and unmeasured confounders given treatment
status, simulations reveal that the adjustments are robust to modest de-
partures from this condition. Moreover, in all conditions we examined the
adjustment reduced bias compared to an unadjusted analysis.
Conditional independence is a generally untestable assumption that is
unlikely to hold exactly in applications. Investigators should therefore eval-
uate patterns of correlation within their data before applying the method.
We recommend exploring the possible size of partial correlations by succes-
sively omitting individual observed confounders and estimating their partial
correlations with the remaining measured confounders. Simulations show
that the adjustment is robust to within-stratum correlations less than 0.15,
a condition that appears to be satisfied in our bladder cancer example.
In some types of studies one expects to find substantial correlations among
measured and unmeasured confounders. For example, in a study to examine
cost of an intervention to improve student performance on a standardized
exam, measured confounders related to socioeconomic status could be highly
correlated with unmeasured confounders such as parental attitudes toward
education. If most measured confounders are tightly interrelated with the
unmeasured variable, this would render our adjustments inaccurate. Here
the investigator should use the method of VanderWeele and Arah (2011),
perhaps with simplifying assumptions about the confounder to render the
procedure more tractable.
A second limitation of our method is that adjustments for strong Pois-
son and Gamma confounders can be biased in moderate sample sizes. The
correction may also leave bias when there is a large proportion of censored
data, as would occur in studies with short follow-up. This is likely due to the
decreased efficiency of the Lin estimator when the proportion of censoring is
high, a problem that could be ameliorated by splitting the time period into
intervals [Lin (2003)] or the creation of a more efficient GLM for censored
costs.
With our simple additive corrections, assuming fixed values of the sensitiv-
ity parameters leads us to use the unadjusted Var(βˆ∗) to develop confidence
intervals. A fully Bayesian approach would quantify uncertainty about the
parameters using prior distributions and propagate the uncertainty using
Bayes’s theorem. One could also conduct a probabilistic sensitivity analysis
using Monte Carlo simulations as demonstrated in Arah, Chiba and Green-
land (2008). Although it is appealing to incorporate uncertainty about the
sensitivity parameters, both methods require sufficient knowledge about un-
measured parameters to fully characterize their distributions.
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Despite its limitations, our method provides a practical approach to evalu-
ate the sensitivity of costs to unmeasured confounding. The bladder cancer
study provides an example where our method can be easily implemented
to evaluate the effect of a wide range of confounders. Further research
should develop extensions to allow sensitivity analysis for combined cost-
effectiveness outcomes.
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